Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia
- 28 November 2016
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (7) , 1764-1766
Abstract
In February 2016, the European Medicines Agency (EMA) released a document stating that, according to available evidence, the marketing authorization holders of BCR-ABL tyrosine-kinase inhibitors (T...Keywords
This publication has 13 references indexed in Scilit:
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013The Lancet, 2015
- Management of patients with hepatitis B who require immunosuppressive therapyNature Reviews Gastroenterology & Hepatology, 2013
- Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case–control study EpilymphJournal of Cancer Research and Clinical Oncology, 2012
- The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivityInternational Journal of Cancer, 2010
- Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature reviewInternational Journal of Hematology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009
- Reactivation of chronic hepatitis B infection related to imatinib mesylate therapyHepatology International, 2008
- Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an updateCytotherapy, 2008
- Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005Hepatology, 2006
- Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatmentLeukemia & Lymphoma, 2006